Comparison of the effectiveness of different oral glucose lowering drugs in fasting patients with type II diabetes
Introduction: Type 2 diabetes is the most common metabolic diseases in developed and developing countries with no effective treatment options. This study purpose was to compare different regimens of oral anti-diabetic therapy effects on the type 2 diabetic patients while fasting during Ramadan. Meth...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Negah Institute for Scientific Communication
2018-04-01
|
| Series: | International Journal of Biomedicine and Public Health |
| Subjects: | |
| Online Access: | http://www.ijbmph.com/article_61057_e131a1a08e565475e7922137717c538a.pdf |
| Summary: | Introduction: Type 2 diabetes is the most common metabolic diseases in developed and developing countries with no effective treatment options. This study purpose was to compare different regimens of oral anti-diabetic therapy effects on the type 2 diabetic patients while fasting during Ramadan. Methods: In the double-blind controlled trial 90 patients with type 2 diabetes were divided randomly into three groups: 30 patients continued the previous dose of sulfonylurea (Group 1), 30 participants received a dose which was 25% lower than the previous sulfonylurea dose (group 2), and in the last 30 patients, repaglinide was replaced sulfonylurea (Group 3). Glucose, glycosylated hemoglobin (HbA1C), fructosamine, total cholesterol, low-density lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides levels were measured in all participants before and after Ramadan. The weight and BMI were also controlled. Results: In all intervention groups a significant decreasing was seen in the body weight, BMI, fructoseamine, total cholesterol, and LDL; and also, a significant increasing was seen in HDL. The hypoglycemia incidence was significantly lower in Group 3 than Group 1. The results in fructosamine reduction and HDL cholesterol increasing were significantly better in Group 3 compared to Group 2 (P<0.05). Significant changes were not seen in total cholesterol, LDL, triglyceride, FBS, and HbA1C levels among the three treatment groups during Ramadan. Conclusion: The repaglinide consumption in comparing with sulfonylurea in patients with diabetes during Ramadan can cause fewer hypoglycemia, and better glycemic, and lipid control. |
|---|---|
| ISSN: | 2588-5375 2588-5375 |